|

Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis

RECRUITINGSponsored by Idoven 1903 S.L.
Actively Recruiting
SponsorIdoven 1903 S.L.
Started2025-05-27
Est. completion2026-03
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06978660

Summary

CONCERTO is a retrospective, observational, multicentric and single-arm study to perform an external validation of the cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named Willem™, to detect Transthyretin cardiac amyloidosis (ATTR-CA). Thus, this study will assess Willem™ ability to distinguish between truly diagnosed ATTR-CA patients and confirmed non-ATTR-CA patients from ECG data.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Subjects ≥ 18 years old
* Subjects with 12-leads ECG records with a 10 seconds minimum length on digital format

Exclusion Criteria:

* Patients with paced rhythm on the ECG.

Conditions2

Heart DiseaseTransthyretin Cardiac Amyloidosis

Locations1 site

Northwestern University
Evanston, Illinois, 60208
Faraz Ahmad, MD, MS

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.